Call for Papers

Eligibility

To submit an abstract, the following criteria must be met:

• At least one of the authors must be an ASH member, who has paid the current membership dues. If none of the abstract authors is an ASH member, the abstract must be sponsored by a current ASH member or it will not be reviewed. ASH members are urged to use their judgment in restricting sponsorship to a reasonable number of abstracts, keeping in mind that they are endorsing the authenticity and quality of each abstract that they sponsor.
• Research and/or studies must fit into one of the ASH Meeting on Hematologic Malignancies 2016 Abstract Review Categories:
• Leukemia
• Lymphoma
• Myelodysplastic Syndromes
• Myeloma
• Myeloproliferative Neoplasms
• Any of the following criteria will make an abstract ineligible for presentation at the ASH Meeting on Hematologic Malignancies:
  • Data are publicly available via major search engines (such as PubMed, Google Scholar, etc.);
  • Data are accepted for publication before the abstract submission closing date;
  • Data have been or are to be presented at a meeting of 1,000 or more participants before the ASH Meeting on Hematologic Malignancies;
  • Data are to be presented at an ASH Friday Satellite Symposium.
• Updated analyses will be considered only if the abstract is a significant extension of previously published work. The author must provide an explanation to show how the abstract contains significant new information.
• Note: Abstracts submitted to the ASH Meeting on Hematologic Malignancies are eligible to be re-submitted to the 2016 ASH Annual Meeting.

Return to Top

Responsibilities of the Presenting Author

• The first author listed for each abstract serves as the presenting author and as the primary contact for all correspondence regarding the abstract, unless otherwise specified under the "Contact Information" section of the online abstract submission system.
• The presenting author must be one of the co-authors listed on the submitted abstract.
• The presenting author is responsible for the following:
• Ensuring that all authors have read the abstract and agreed to be co-authors. Failure to get approval from all authors will result in rejection of the abstract.
• Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by ASH.
• Obtaining all the conflict of interest disclosure and copyright transfer information from co-authors.
• Forwarding all correspondence to all co-authors, including the ASH policies and guidelines, and the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support for Continuing Medical Education (CME).

Return to Top

Technical Requirements

The electronic submission system is compatible with PC Windows and Apple computers and with most browsers, including Google Chrome, Mozilla Firefox, Internet Explorer, Safari, and Netscape. However, Mac users are encouraged to use Mozilla Firefox.

Return to Top

Before you Begin

Return to Top

Submission Process

FAQS

Please consider the following before submitting your abstract to the 2016 ASH Meeting on Hematologic Malignancies:

• Q: What is the submission deadline for the abstracts?
  A: The deadline for all abstracts is July 13th, 2016 at 11:59 p.m. PDT. Submissions that are incomplete at this time will be rejected without review.
• Q: Can I still submit an abstract if I presented it at another scientific meeting or submitted it to a journal?
  A: Any of the following criteria will make an abstract ineligible for presentation at the ASH Meeting on Hematologic Malignancies:
• Data are publicly available via major search engines (such as PubMed, Google Scholar, etc.);
• Data are accepted for publication before the abstract submission closing date;
• Data have been or are to be presented at a meeting of 1,000 or more participants before the ASH Meeting on Hematologic Malignancies

Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown. In this case, please use the Updated Analyses section of the abstract form to explain the significance of the new data. The reviewers will have this information available during their evaluation.

• Q: How long can the abstracts be?
  A: The abstracts are limited to a maximum of 3,800 characters. Note that this character count does not include spaces but does include the space allocated to tables. Figures are not included in the character count.
• Q: If I have images in my abstract, what resolution should my images be?
  A: We require a minimum of 300 dpi for all uploaded images. This will insure proper resolution for display.
• Q: How many abstracts can a single author submit?
  A: There is no set limit as to the number of abstracts a single author can submit.
• Q: How many authors can contribute to a single abstract?
  A: There is no set limit to the number of authors who can contribute to a single abstract.
• Q: Do all authors on an abstract have to submit their Conflict-of-Interest disclosures to ASH? How should they do that?
  A: The submitting author must manually enter disclosure information for all authors into the online abstract submission form. You may wish to use this sample form to collect disclosure information from your coauthors. (Please note that this form should NOT be sent to ASH; you are responsible for entering the information on the form into the online abstract submission system for every author.)
• Q: What if I am not able to submit my abstract at this time?
  A: A late submission window will not be offered for this meeting.
• Q: When will I know if my abstract has been accepted?
  A: You will receive an e-mail by August 1st notifying you if your abstract has been accepted and whether you are invited to present it at the ASH Meeting on Hematologic Malignancies.

Return to Top